1.52 USD
+0.03 (+2.01%)
1.53 USD
+0.01 (+0.66%)
Overall AKBA gets a fundamental rating of 4 out of 10. We evaluated AKBA against 530 industry peers in the Biotechnology industry. There are concerns on the financial health of AKBA while its profitability can be described as average. AKBA has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year AKBA has reported negative net income.
AKBA had a positive operating cash flow in the past year.
AKBA had negative earnings in each of the past 5 years.
AKBA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AKBA's Return On Assets of -4.37% is amongst the best of the industry. AKBA outperforms 86.42% of its industry peers.
Looking at the Return On Equity, with a value of -38.24%, AKBA is in the better half of the industry, outperforming 71.89% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 6.90%, AKBA belongs to the top of the industry, outperforming 93.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| ROIC | 6.9% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AKBA has a better Operating Margin (8.95%) than 90.94% of its industry peers.
AKBA has a Gross Margin of 82.52%. This is amongst the best in the industry. AKBA outperforms 86.04% of its industry peers.
AKBA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.95% | ||
| PM (TTM) | N/A | ||
| GM | 82.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AKBA is destroying value.
The number of shares outstanding for AKBA has been increased compared to 1 year ago.
Compared to 5 years ago, AKBA has more shares outstanding
The debt/assets ratio for AKBA is higher compared to a year ago.
2.2 Solvency
AKBA has an Altman-Z score of -4.48. This is a bad value and indicates that AKBA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of AKBA (-4.48) is worse than 60.00% of its industry peers.
The Debt to FCF ratio of AKBA is 5.97, which is a neutral value as it means it would take AKBA, 5.97 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.97, AKBA belongs to the top of the industry, outperforming 91.51% of the companies in the same industry.
A Debt/Equity ratio of 4.30 is on the high side and indicates that AKBA has dependencies on debt financing.
With a Debt to Equity ratio value of 4.30, AKBA is not doing good in the industry: 80.19% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 5.97 | ||
| Altman-Z | -4.48 |
ROIC/WACC0.87
WACC7.91%
2.3 Liquidity
AKBA has a Current Ratio of 1.94. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.94, AKBA is doing worse than 76.42% of the companies in the same industry.
AKBA has a Quick Ratio of 1.80. This is a normal value and indicates that AKBA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.80, AKBA is doing worse than 76.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
AKBA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.57%, which is quite impressive.
The Revenue has grown by 32.49% in the past year. This is a very strong growth!
Measured over the past years, AKBA shows a very negative growth in Revenue. The Revenue has been decreasing by -13.72% on average per year.
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%
3.2 Future
AKBA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.23% yearly.
Based on estimates for the next years, AKBA will show a very strong growth in Revenue. The Revenue will grow by 23.72% on average per year.
EPS Next Y113.6%
EPS Next 2Y53.22%
EPS Next 3Y36.92%
EPS Next 5Y26.23%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.81%
Revenue Next 5Y23.72%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AKBA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 13.25, the valuation of AKBA can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AKBA indicates a rather cheap valuation: AKBA is cheaper than 97.17% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.88. AKBA is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.25 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AKBA is valued cheaper than 95.09% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AKBA is valued cheaply inside the industry as 97.74% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.54 | ||
| EV/EBITDA | 13.83 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AKBA's earnings are expected to grow with 36.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.22%
EPS Next 3Y36.92%
5. Dividend
5.1 Amount
AKBA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.52
+0.03 (+2.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners47.63%
Inst Owner Change0%
Ins Owners3.57%
Ins Owner Change0%
Market Cap403.36M
Revenue(TTM)225.07M
Net Income(TTM)-15.90M
Analysts87.27
Price Target5.51 (262.5%)
Short Float %13.83%
Short Ratio7.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)100%
Min EPS beat(2)100%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)85.7%
Min EPS beat(4)-22.55%
Max EPS beat(4)165.36%
EPS beat(8)5
Avg EPS beat(8)49.92%
EPS beat(12)8
Avg EPS beat(12)29.94%
EPS beat(16)9
Avg EPS beat(16)25.61%
Revenue beat(2)1
Avg Revenue beat(2)14.3%
Min Revenue beat(2)-1.07%
Max Revenue beat(2)29.66%
Revenue beat(4)3
Avg Revenue beat(4)18.97%
Min Revenue beat(4)-1.07%
Max Revenue beat(4)29.66%
Revenue beat(8)3
Avg Revenue beat(8)1.71%
Revenue beat(12)4
Avg Revenue beat(12)-0.75%
Revenue beat(16)8
Avg Revenue beat(16)11.83%
PT rev (1m)0%
PT rev (3m)-27.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)46.43%
EPS NY rev (1m)0%
EPS NY rev (3m)300%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.25 | ||
| P/S | 1.79 | ||
| P/FCF | 12.54 | ||
| P/OCF | 12.45 | ||
| P/B | 9.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 13.83 |
EPS(TTM)-0.07
EYN/A
EPS(NY)0.11
Fwd EY7.55%
FCF(TTM)0.12
FCFY7.98%
OCF(TTM)0.12
OCFY8.03%
SpS0.85
BVpS0.16
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -38.24% | ||
| ROCE | 8.73% | ||
| ROIC | 6.9% | ||
| ROICexc | 24.74% | ||
| ROICexgc | 301.13% | ||
| OM | 8.95% | ||
| PM (TTM) | N/A | ||
| GM | 82.52% | ||
| FCFM | 14.3% |
ROA(3y)-26.46%
ROA(5y)-38.48%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.75%
GM growth 5Y4.73%
F-Score4
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.3 | ||
| Debt/FCF | 5.97 | ||
| Debt/EBITDA | 5.88 | ||
| Cap/Depr | 2.17% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 106.44% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | -4.48 |
F-Score4
WACC7.91%
ROIC/WACC0.87
Cap/Depr(3y)0.13%
Cap/Depr(5y)0.3%
Cap/Sales(3y)0.02%
Cap/Sales(5y)0.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)69.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y113.6%
EPS Next 2Y53.22%
EPS Next 3Y36.92%
EPS Next 5Y26.23%
Revenue 1Y (TTM)32.49%
Revenue growth 3Y-8.88%
Revenue growth 5Y-13.72%
Sales Q2Q%57.01%
Revenue Next Year58.44%
Revenue Next 2Y39.29%
Revenue Next 3Y28.81%
Revenue Next 5Y23.72%
EBIT growth 1Y162.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y142.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y142.77%
OCF growth 3YN/A
OCF growth 5YN/A
AKEBIA THERAPEUTICS INC / AKBA FAQ
What is the fundamental rating for AKBA stock?
ChartMill assigns a fundamental rating of 4 / 10 to AKBA.
What is the valuation status for AKBA stock?
ChartMill assigns a valuation rating of 6 / 10 to AKEBIA THERAPEUTICS INC (AKBA). This can be considered as Fairly Valued.
How profitable is AKEBIA THERAPEUTICS INC (AKBA) stock?
AKEBIA THERAPEUTICS INC (AKBA) has a profitability rating of 4 / 10.
What is the financial health of AKEBIA THERAPEUTICS INC (AKBA) stock?
The financial health rating of AKEBIA THERAPEUTICS INC (AKBA) is 3 / 10.